Cours suspendu

Communiqués Achilles Therapeutics plc

Actions

ACHL

US00449L1026

Sociétés holdings

Marché Fermé - Nasdaq 21:00:00 20/03/2025			Varia. 5j.	Varia. 1 janv.
1,480 ^USD	+0,68%		-.--%	-

05/02/25	Achilles Therapeutics, société du portefeuille de Syncona, poursuit sa liquidation volontaire	MT
04/02/25	Sergio Quezada quitte son poste de directeur scientifique d'Achilles Therapeutics plc	CI

Communiqués

28/02/25	Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration	AQ
27/12/24	Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca	AQ
26/12/24	Achilles Therapeutics : Announces Sale of Technology Assets to AstraZeneca Form 6 K	PU
24/12/24	Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca	AQ
02/12/24	Achilles Therapeutics : Information Contained in this Report on Form 6 K Form 6 K	PU
19/11/24	Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market	AQ
14/11/24	Achilles Therapeutics : Reports Third Quarter 2024 Financial Results Form 6 K	PU
14/11/24	Achilles Therapeutics Reports Third Quarter 2024 Financial Results	AQ
05/11/24	TIL Summit – Boston – October 2024: Targeting Clonal Neoantigens with Precision Cell Therapies	PU
19/09/24	Achilles Therapeutics Announces Strategic Update	AQ
15/08/24	Achilles Therapeutics : Corporate Presentation – August 2024	PU
14/08/24	Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates	AQ
05/08/24	Achilles Therapeutics : Information Contained in this Report on Form 6 K Form 6 K	PU
27/06/24	Achilles Therapeutics : Results of Annual General Meeting Form 6 K	PU
24/05/24	Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	PU
22/05/24	Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	AQ
20/05/24	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	AQ
17/05/24	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	AQ
08/05/24	Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	AQ
04/04/24	Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	AQ
04/04/24	Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	AQ
05/02/24	Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	AQ
18/12/23	Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	AQ
13/11/23	Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights	AQ
22/09/23	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	AQ